Table 3 The main pharmacokinetic parameters of rifaximin in mammary glands following an intramammary administration with a single dose of 50, 100, 200, and 400 μg/gland in mice, analyzed by non-compartment and two-compartment models

non-compartment

 T_1/2

6.18

7.45

6.84

7.19

6.92 ± 0.48

 MRT

6.76

7.42

6.80

7.11

7.02 ± 0.27

 AUC₂₄

170.23

414.31

653.22

1287.03

 C_max

25.01

49.73

83.17

162.17

two-compartment models

 MRT

9.10

11.34

9.08

10.46

10.00 ± 0.96

 AUC₂₄

175.41

469.08

677.08

1400.29

 Cmax

27.08

53.07

87.31

165.99

 V₁

1.85

1.88

2.29

2.41

2.11 ± 0.28

 CL₁

0.29

0.21

0.30

0.29

2.07 ± 0.04

 V2

0.75

0.53

0.39

0.58

0.56 ± 0.15

 CL₂

1.13

1.21

1.14

0.40

0.97 ± 0.38